Skip to main content

Cobimetinib in Treating Patients with Histiocytic Disorders

Trial Status: Active

This phase II trial studies how well cobimetinib works in treating patients with histiocytic disorders. Histiocytic disorders are a group of diseases that occur when there is an over-production of white blood cells known as histiocytes that can lead to organ damage and tumor formation. Cobimetinib may work by blocking a gene that may be responsible for these processes, which may stop tumors from forming.

Inclusion Criteria

  • Histologically confirmed histiocytic disorder or histologic findings compatible with a histiocytic disorder in the context of confirmatory radiologic findings confirmed by the enrolling institution
  • One of the following: * Documentation of BRAF V600E mutation and inability to access BRAF inhibitor or prior treatment with a BRAF inhibitor discontinued due to intolerable side effects or toxicity prior to progression OR * Documentation of wild-type BRAF V600 mutational status; patients with BRAF-mutated Erdheim-Chester disease (ECD)/Langerhans cell histiocytosis (LCH) who have had disease progression on BRAF inhibitor therapy would be eligible but would require tissue biopsy (or available tissue) for genotyping before participating
  • Measurable disease according to PET Response Criteria, confirmed by an Memorial Sloan Kettering (MSK) investigator radiologist, with the exception of patients with cutaneous disease that can be measured and followed by RECIST criteria
  • Histiocytic disorder must be (a) multi-system disease or (b) disease that is recurrent or refractory to standard therapies, or (c) single-system disease that is unlikely to benefit from conventional and less toxic therapies, based on the best available evidence (for example, central nervous system [CNS] or cardiac infiltration, retroperitoneal fibrosis, prior chemotherapy, or other medical history or co-morbidities, etc)
  • Life expectancy > 12 weeks
  • Eastern Cooperative Oncology Group (ECOG) performance status =< 3 (may be converted from Karnofsky performance status)
  • Absolute neutrophil count (ANC) > 1000/uL
  • Platelets >= 50,000/uL
  • Hemoglobin >= 8.5 g/dL
  • Patients with cytopenias below these thresholds deemed to be the result of disease will be considered eligible
  • Creatinine =< 1.5 x the upper limit of normal (ULN) OR * Estimated creatinine clearance of > 50 ml/min * Patients with renal dysfunction deemed to be the result of disease will be considered eligible
  • Bilirubin =< 1.5 x ULN
  • Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
  • Ability to swallow pills
  • Negative pregnancy test within 7 days prior to commencement of dosing in premenopausal women, women of non childbearing potential may be included without serum pregnancy test if they are either surgically sterile or have been postmenopausal for >= 1 year
  • Fertile men and women must use an effective method of contraception during treatment and for at least 6 months after completion of treatment as directed by their physician; effective methods of contraception are defined as those which result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly (for example implants, injectables, combined oral contraception or intra-uterine devices); at the discretion of the investigator, acceptable methods of contraception may include total abstinence in cases where the lifestyle of the patient ensures compliance (periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception)
  • Patients must be willing to consent for protocol #12-245 for IMPACT testing (for MSK patients ONLY)

Exclusion Criteria

  • Prior treatment with a mitogen-activated protein kinase (MEK) inhibitor
  • Active infection requiring intravenous antibiotics
  • Pregnant, lactating or breast feeding women
  • Prior radiation therapy within the last 14 days
  • Unwillingness or inability to comply with study and follow-up procedures
  • Any foods/supplements that are strong inhibitors or inducers of CYP3A are prohibited at least 7 days prior to initiation of and during study treatment
  • History of or evidence of retinal pathology or ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration
  • The risk factor for RVO are listed below; exclusion should be considered by clinical discretion if they have the following conditions: * Uncontrolled glaucoma with intra-ocular pressures > 21 mmHg * Serum cholesterol >= grade 2 * Hypertriglyceridemia >= grade 2 * Hyperglycemia >= grade 2
  • History of clinically significant cardiac dysfunction, unless deemed to be direct result of disease, including the following: * Current unstable angina * Symptomatic congestive heart failure of New York Heart Association (NYHA) class 2 or higher * Uncontrolled hypertension > grade 2 (patients with history of hypertension controlled with anti-hypertensives to =< grade 2 are eligible) * Left ventricular ejection fraction (LVEF) below institutional lower limit of normal or below 50% * Uncontrolled arrhythmias * Myocardial infraction, severe/unstable angina, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack within the previous 6 months

New York

New York
Memorial Sloan Kettering Cancer Center
Status: ACTIVE
Contact: Eli L. Diamond
Phone: 212-610-0243


I. Best overall response rate according to Positron Emission Tomography (PET) Response Criteria (PRC).


I. Best overall response rate according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) (for the subset of patients with RECIST-measurable disease).

II. The following secondary objectives will be based on response and progression as defined by the PRC: time to progression; progression free survival; duration of response; clinical benefit rate (for patients with complete response [CR], partial response [PR], or stable disease).

III. Overall survival.

IV. Safety of cobimetinib in patients with histiocytosis.


I. Response as determined by mutational allele burden in plasma cell free deoxyribonucleic acid (DNA).

II. Exploratory quality of life (QOL) and patient-reported outcome (PRO) responses.


Patients receive cobimetinib orally (PO) once daily (QD) on days 1-21. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity. Patients have the option to discontinue treatment after the completion of 12 cycles and begin disease monitoring for 12 months. Patients who experience disease relapse during 12 months of disease monitoring may then restart treatment with cobimetinib. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 28 days and then every 3 months for at least 12 months.

Trial Phase Phase II

Trial Type Treatment

Lead Organization
Memorial Sloan Kettering Cancer Center

Principal Investigator
Eli L. Diamond

  • Primary ID 15-216
  • Secondary IDs NCI-2016-00061
  • ID NCT02649972